4 Promising Drug Developments in Psoriatic Arthritis Treatment Market

1
4 Promising Drug Developments in Psoriatic
Arthritis Treatment Market
According to the latest data from the National
Psoriasis Foundation, over 8 million people in
the United States have psoriasis. In psoriatic
arthritis, the underlying inflammation affects
bodily systems like the lungs, heart, and eyes.
One primary goal in treating psoriatic arthritis
or psoriasis is achieving skin clearance. As per
Inkwood Research, the global psoriatic arthritis
treatment market growth is anticipated to
progress at a CAGR of 7.64 during 2023-2032.

• This blog discusses the four promising drug
  developments for psoriatic arthritis treatment.
• Sun Pharma announces China NMPA Approval for
  ILUMETRI
• On 30th May 2023, Sun Pharmaceutical Industries
  announced the approval of a New Drug Application
  (NDA) for tildrakizumab injection under ILUMETRI
  by the National Medical Products Administration
  of the People's Republic of China.
• ILUMETRI is indicated for treating adults with
  moderate-to-severe plaque psoriasis who are
  candidates for phototherapy or systemic therapy.
  In June 2019, tildrakizumab was out-licensed by a
  China Medical System Holdings Limited (CMS)
  subsidiary for commercialization, regulatory
  filings, and development of the product in
  Greater China.
• As per CMS, the Phase III clinical trial results
  showed a continual increase in the primary
  efficacy assessment indicator PASI 75 response
  over the treatment time. Tildrakizumab Injection
  has also been approved in the United Kingdom, the
  United States, Japan, European Union, Hong Kong,
  Australia, Canada, Switzerland, etc., under
  brands like ILUMETRI and ILUMYA.
• BIOCAD showcases Netakimab's efficacy at EULAR
  2020

2

• Netakimab is an anti-interleukin 17A antibody
  approved and humanized for treating moderate-to-
  severe plaque psoriasis. The phase III clinical
  trial PATERA assessed the Netakimab's effects on
  the symptoms and signs of psoriatic arthritis,
  including quality of life, skin manifestation,
  and disease activity.
• The trial included 194 eligible psoriatic
  arthritis patients who received either a placebo
  or 120 mg of Netakimab subcutaneously for 24
  weeks. The drug was well-endured and the effects
  were mild to moderate. No anti-drug antibodies
  were detected and no treatment-related severe
  adverse effects.
• Priovant Therapeutics' Brepocitinib on a Unique
  Quest
• Brepocitinib is a drug being tested for possible
  treatment for many immunocompromising conditions
  like dermatomyositis, ulcerative colitis, and
  systemic lupus erythematosus. However,
  Brepocitinib's phase II trial has also exhibited
  positive outcomes for psoriatic arthritis
  treatment.
• Further, Brepocitinib works by hindering the
  inflammation-causing immune response, which forms
  the core of psoriatic arthritis. The drug is
  unique since it obstructs two enzymes, JAK1 and
  TYK2, which play a huge role in autoimmune
  disease. Presently, Brepocitinib is the only dual
  inhibitor in late-stage development.
• Dr. Ruth Ann Vleugels, a principal investigator
  for the Priovant study of Brepocitinib in
  dermatomyositis, says, "Years of experience using
  JAK inhibitors in patients with dermatomyositis
  has shown us that these agents can profoundly
  benefit patients with uncontrolled disease. Given
  the devastating manifestations of dermatomyositis
  and its substantial impact on quality of life,
  the benefits of treatment with JAK inhibitors
  outweigh the potential risks in the vast majority
  of patients in our clinic." (Source)
• AbbVie gets FDA approval for SKYRIZI
  (risankizumab-rzaa)
• On 21st January 2022, AbbVie announced the U.S.
  Food and Drug Administration (FDA) 's approval of
  SKYRIZI for treating adults with active
  psoriatic arthritis. The approval is supplemented
  by data from two pivotal studies, KEEPsAKE-1 and
  KEEPsAKE-2. These studies assessed SKYRIZI's
  safety and efficacy in adults with active
  psoriatic arthritis.
• SKYRIZI dictates a dosing procedure for psoriatic
  arthritis, which is in tandem with the existing
  procedure for moderate-to-severe plaque psoriasis
  patients. It displayed considerable improvements
  across many manifestations of psoriatic
  arthritis, including painful, tender, and swollen
  joints.
• Says Alan J. Kivitz, M.D, clinical trial
  investigator of KEEPsAKE, "In the pivotal
  KEEPsAKE trials, SKYRIZI demonstrated
  improvements across a number of psoriatic
  arthritis symptoms, including joint pain,
  enthesitis and dactylitis. This approval provides
  both dermatologists and rheumatologists with an
  option that helps improve skin and joint symptoms
  in patients with active psoriatic arthritis,
  alongside a quarterly dosing schedule that may
  fit their patients' lifestyle." (Source)
• Such product developments enhance the global
  psoriatic arthritis treatment market growth
  prospects.
• FAQs
• Which is the largest revenue-generating region in
  the global psoriatic arthritis treatment market?

3

• A North America is the largest
  revenue-generating region in the global psoriatic
  arthritis treatment market.
• Which is the prominent drug type in the global
  psoriatic arthritis treatment market?
• A Disease-modifying antirheumatic drugs (DMARDs)
  are the prominent drug type in the global
  psoriatic arthritis treatment market.